I
n the United States, heart failure (HF) affects ≈6.5 million adults, 1 and lifetime risk of HF is estimated to be 1 in 5 at 40 years of age. 2 Incidence of HF increases with age, and HF prevalence in the aging US population is projected to increase by 46% between 2012 and 2030. 3 Older adults diagnosed with HF have a 5-year mortality approaching 50%. 4, 5 Total direct medical costs of HF were estimated at $30.7 billion in 2012 and are projected to increase by ≈127% to $69.7 billion by 2030. 3 Evidence-based interventions exist to prevent or manage HF, yet suboptimal care has been cited as a reason for poor HF-related outcomes in the United States. 6 For example, despite many HF hospitalizations being considered preventable, 6 HF is the leading cause of hospitalization among older adults, and Medicare beneficiaries with HF have the highest readmission rate of any condition. 7 In response, reducing preventable hospitalizations has been made a national priority. This includes creating the Hospital Readmissions Reduction Program (HRRP) through the enactment of the Patient Protection and Affordable Care Act in 2010. 8, 9 Effective October 1, 2012, the HRRP requires the Centers for Medicare & Medicaid Services to reduce payments to hospitals with excess readmissions for certain conditions, including HF. 10 Although HF has considerable health and economic impact, and reducing the burden of HF hospitalizations has been the focus of legislative, policy, and public health attention, there is no comprehensive national surveillance system to track HF-related healthcare and mortality burden across all ages and all health insurance provider types in the United States. The purpose of this study was to address this surveillance gap using national Healthcare Cost and Utilization Project (HCUP) and National Vital Statistics System data from 2006 to 2014. Specifically, we aimed to describe the burden of HF in emergency department (ED) visits, inpatient hospitalizations and costs, and mortality, including both primary HF events and events in which HF was listed as a comorbidity.
METHODS
Using data from the HCUP Nationwide Emergency Department Sample, the National (Nationwide) Inpatient Sample (NIS), and the National Vital Statistics System, this cross-sectional study examined ED visits, hospitalizations, and deaths, respectively, during 2006 to 2014. The largest all-payer ED database in the United States, the Nationwide Emergency Department Sample includes data from ≈30 million annual discharges across 950 hospitals in 30 states. These data approximate a 20% stratified sample of US hospitalbased EDs and are weighted to produce national estimates. 11 The NIS includes data from >7 million hospitalizations annually and is the largest publicly available all-payer inpatient healthcare database in the United States. Data approximate a 20% stratified sample of discharges from US community hospitals (including teaching hospitals but excluding rehabilitation and long-term acute care hospitals) and are weighted to produce national estimates of hospitalizations. 12 The NIS was redesigned in 2012, and the Agency for Healthcare Research and Quality developed trend weights to make estimates comparable for data before 2012. Created by the National Center for Health Statistics, the National Vital Statistics System collects data from death certificates filed in every US state and the District of Columbia. 13 All events for US adults aged ≥18 years were included. The data used are publicly available to other researchers, and analytic methods will be shared on request for the purpose of reproducing results.
Conditions of interest were identified by applying adapted Clinical Classification Software codes, created by the Agency for Healthcare Research and Quality (Table I in 
WHAT IS NEW?
• Heart failure (HF) is burdensome and costly, yet a comprehensive national surveillance system is lacking.
• We report primary (≈1.1 million emergency department visits, 1 million hospitalizations, and 80 000 deaths) and comorbid (4 million emergency department visits, 3.4 million hospitalizations, and 230 000 deaths) HF burden in 2014.
• Of hospitalizations with primary HF, the estimated mean cost was $11 552 in 2014, with a total estimated cost of >$11 billion; Medicare incurs the majority of this burden.
• Between 2006 and 2014, the age-standardized total unique acute event rate for primary HF decreased, whereas the comorbid HF event rate increased.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Although national initiatives, such as the Hospital Readmissions Reduction Program, may have supported progress in reducing HF readmissions, the rate of primary HF hospitalization was already decreasing at the time of implementation, and trends in HF-related emergency department visits, comorbid hospitalizations, and mortality have not improved.
• Positive trends in some HF risk factors, such as declines in ischemic heart disease, may be decreasing HF incidence and event burden, whereas advances in HF management may be increasing survival and improving outcomes.
• Given increasing HF prevalence and an aging US population, continued improvements in HF prevention, management, and surveillance are important.
Statistics System. Events for which HF was listed as a primary diagnosis or underlying cause of death (referred to as primary HF) were examined separately from events for which HF was listed as a comorbid diagnosis or contributing cause of death (referred to as comorbid HF). Because of uncertainty on the accuracy of HF coded as an underlying cause of death, 14, 15 we examined trends in combined HF-related deaths (listed as either an underlying or contributing cause of death), in addition to reporting primary or comorbid HF deaths separately. Additional conditions that have been associated with HF, including those affecting the lungs (asthma, chronic obstructive pulmonary disease, and pneumonia), cardiometabolic conditions (atrial fibrillation and flutter [AF] , chronic kidney disease, diabetes mellitus, hypertension, ischemic heart disease [IHD], and stroke [both ischemic and hemorrhagic]), and mental health conditions (depression, dementia, or Alzheimer), were examined as both primary and comorbid diagnoses. 1, 16 Event totals were calculated for each event type (ED visits, hospitalizations, and deaths), to examine overall health system and mortality burden related to HF. For these analyses, hospitalization totals included both elective and acute hospitalizations because both types of hospitalization contribute to burden and cost.
For a second set of analyses examining trends over time, exclusion criteria were applied to each event type to identify unique (mutually exclusive) events, to avoid double-counting, and to identify acute events (so that observed temporal changes would not be confounded by shifts in management of elective procedures in the inpatient or outpatient setting). To do this, ED visits that resulted in hospitalization, transfer to another facility, or death were excluded, as were hospitalizations that resulted in transfer to another hospital or death, or hospitalizations that were reported as elective. 17, 18 Thus, unique ED visits, unique acute hospitalizations, and deaths were summed to estimate the overall unique acute event burden, which reflects the total number of acute events that could be targeted by public health and health system prevention efforts. In addition, estimating unique acute events allowed us to assess trends in treat-and-release ED visits (ie, ED visits that did not result in hospitalization, transfer, or death), which are of interest given the unique role of the ED, the cost implications of ED use for patients and the healthcare system, the number of patients who need care but may not be ill enough for inpatient admission, and also recent speculation that hospitals may be increasing the use of the ED and observation service to avoid inpatient admissions. 19, 20 Hospitalization costs were estimated from total charges using hospital-level cost-to-charge ratios provided by HCUP. Charges represent what the hospital billed for the case and do not include professional (physician) fees. Cost-to-charge ratio data were not available for ED visits, so ED costs could not be estimated.
Event rates were calculated using intercensal population estimates as the denominators 21, 22 and were standardized by age to the 2010 US population. To identify different patterns in HF rates, we conducted trend analyses based on the age-standardized unique event rates using Joinpoint software (version 4.3.1.0 National Cancer Institute). Joinpoint regression fits a series of joined straight lines on a logarithmic scale to the trend data. Analyses were conducted in SAS 9.3-callable SUDAAN (Research Triangle Institute, Research Triangle Park, NC) to account for the multistage, disproportionate stratified sampling design of the HCUP datasets. Wilcoxon rank-sum tests (2 sided) or t tests were used for statistical comparisons of continuous variables, and χ 2 tests were used for categorical variables. The data were deidentified and publicly available, and thus this project was determined not to be human subjects research.
RESULTS
In 2014, there were ≈1.1 million ED visits, 980 000 hospitalizations, and 84 000 deaths with primary HF (Table 1 ). In addition, there were ≈4.1 million ED visits, 3.4 million hospitalizations, and 231 000 deaths with comorbid HF ( Table 2) . As expected, patients with either primary or comorbid HF were significantly older than patients without HF, and ≈3 quarters of ED visits and hospitalizations for both primary and comorbid HF were among Medicare beneficiaries (Tables 1 and 2 ). Among hospitalizations for primary HF, the most common comorbid diagnoses were hypertension (72%), IHD (56%), diabetes mellitus (48%), chronic kidney disease (47%), and AF (43%; Table 1 ). Among deaths with comorbid HF, the most common underlying causes were IHD (44%), hypertension (21%), and chronic obstructive pulmonary disease (21%; Table 2 ).
The majority (82%) of ED visits for primary HF resulted in hospital admission or transfer to another facility (Table 3) . For all hospitalizations with primary HF, the median length of stay was 3 days (interquartile range, 2-6), the estimated mean cost was ≈$11 552 (SE, $163), and the total estimated cost was $11.3 billion in 2014 (cost×estimated number of primary HF hospitalizations). Among patients with a primary diagnosis of asthma, chronic obstructive pulmonary disease, pneumonia, AF, diabetes mellitus, IHD, stroke, or depression, the presence of comorbid HF was associated with significantly higher hospitalization cost compared with patients with these primary diagnoses but without HF (P<0.001 for all).
There were ≈1.1 million total unique acute events with primary HF and 4.3 million total unique acute events with comorbid HF, in 2014 (Table 4) . Overall, the age-standardized total unique primary HF event rate (including ED visits, hospitalizations, and deaths) declined significantly from 536 to 449 per 100 000 population between 2006 and 2014 (relative percentage change [RPC] of -16%; P for trend, <0.001; Figure 1; Table II in the Data Supplement). For comorbid HF, the total unique acute event rate increased significantly from 1 467 to 1 689 per 100 000 between 2006 and 2014 (RPC of 15%; P for trend, <0.001).
Trends in unique acute hospitalizations and ED visits (ie, treat-and-release ED visits) were examined to assess whether burden may have shifted from the inpatient to the ED setting. While the unique acute hospitalization rate for primary HF declined significantly from 427 to 341 per 100 000 (RPC of -20%; P for trend, <0.001; Figure 2 ; Table III in the Data Supplement), the treat-andrelease ED visit rate for primary HF also declined significantly between 2006 and 2011 (78-63 per 100 000; P for trend, <0.001) and then did not change significantly (75 per 100 000 in 2014; P for trend, 0.1). Thus, while possible, it does not appear likely that a decline in primary HF hospitalizations was created by shifting burden to the ED in the form of primary HF treat-and-release ED visits. While comorbid treat-and-release ED visits did increase during this time (from 308 to 535 per 100 000; RPC of 74%, P for trend <0.001, Figure 2 , Table IV in the Data Supplement), there was no evidence of a change in the slope of increase in comorbid HF ED visits at the time of HRRP implementation, as might be expected if policy incentives were driving this increase.
The total HF-related mortality rate (including both primary and comorbid HF) decreased significantly during 2006 to 2009 (127-119 per 100 000; P for trend, <0.001) and then did not change meaningfully (124 per 100 000 in 2014; P for trend, 0.1; Figure 2 ). Combined HF-related event rates (including both primary and comorbid HF) for unique ED visits, hospitalizations, deaths, and total events are presented in Table V and Figure I in the Data Supplement.
DISCUSSION
The burden of HF in the United States is considerable. In 2014, there were around 1.1 million ED visits, 1.0 million hospitalizations, and 84 000 deaths with HF as the primary cause. In addition, there were an additional 4.1 million ED visits, 3.4 million hospitalizations, and 231 000 deaths with HF as a comorbid or contributing cause. For hospitalizations with primary HF, the estimated mean cost was $11 552 in 2014, with a total estimated cost of >$11 billion. Among hospitalizations for primary HF, the most common comorbid diagno- ses were hypertension (almost 3 of every 4), IHD (>1 of every 2), diabetes mellitus (≈1 of every 2), chronic kidney disease (≈1 of every 2), and AF (>2 of every 5). Compared with patients without HF, patients who were hospitalized with comorbid HF had significantly higher costs for primary diagnoses of asthma, chronic obstructive pulmonary disease, pneumonia, AF, diabetes mellitus, IHD, stroke, or depression. Despite significant declines from 2006 to 2014, the total unique acute HF event burden remained high, with ≈1.1 million primary HF events and 4.3 million comorbid HF events occurring in 2014. This includes the age-standardized rate of unique acute hospitalizations with primary HF declining significantly from 427 to 341 per 100 000 (RPC of 20% decline). Although national initiatives, such as the HRRP, may have helped continue progress in reducing HF readmissions, including among Medicare beneficiaries, as well as with broader spillover effects across the healthcare system, 23 the rate of primary HF hospitalization was already decreasing at the time of implementation in 2012. This observation is consistent with other studies that have reported declines in HF hospitalization before recently implemented policy changes. For example, a 29.5% decline in age-, sex-, and race-adjusted HF hospitalization was observed between 1998 and 2008 in the Medicare population of adults aged ≥65 years, 24 whereas a study using NIS data for all hospitalizations among adults aged ≥18 years showed an average annual rate of decline of 2.8% between 2001 and 2009. 25 Declines in hospitalization burden are noteworthy, as survival of patients with HF has improved, and would be expected to increase HF prevalence and hospitalizations. 4, 26 On the contrary, positive trends in some HF risk factors, such as better control of hypertension and declines in IHD, may be decreasing HF incidence and event burden. 1 Changes in these risk factors may have substantial impact because hypertension and IHD are estimated to each account for the development of about 20% of HF cases, 27 and HF incidence has been steady or declining in recent decades. 4, 28 Additionally, hospitalizations and outcomes for HF may be improved by better treatment, including newer treatment modalities, such as implantable cardioverter defibrillators, cardiac resynchronization therapy, and left ventricular assist devices, as well as better adherence to recommended guidelines for care, such as use of β-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and better care for comorbidities, such as anticoagulant therapy for AF. 26, 29, 30 Lastly, and potentially related to better management of HF, some HF care may have shifted to the outpatient setting, reducing inpatient hospitalizations. Crude age-and sex-specific rates were reported for subgroup estimates. ED indicates emergency department; and HF, heart failure. *Standardized by age to the 2010 US Census population distribution among adults aged ≥18 y. †Nonelective hospitalizations.
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Better HF treatment and improved survival may have contributed to the observed increase in comorbid HF ED visits 26, 29 because patients living longer with HF would be expected to have more time to develop a need for emergency care for other conditions. In addition, it has been hypothesized that some hospitals might increase the use of ED treatment or observation service to decrease HF readmissions 19, 32 (observation service may occur within or outside of the ED, and thus our unique treat-and-release ED estimates may have captured some but not all observation-service use). In the present study, we did not observe evidence of this potential shift, given that the primary HF ED treat-andrelease visit rate did not increase, and while the comorbid HF ED visit rate did increase, there was no change in slope of the increase at the time of HRRP implementation. Using Medicare data, Zuckerman et al 33 reported increased use of observation service and decreased readmissions for HRRP-targeted conditions, but did not detect within-hospital association between increases in observation-service use and reductions in readmissions.
In addition to potential changes in use of the ED and observation service, it is possible that some hospitals may shift coding of HF from a primary to a comorbid diagnosis and also that coding of HF as a comorbid diagnosis may be increasing more generally. 34 However, the present study observed a stable rate of unique acute comorbid HF hospitalizations and a steady increase in the ED visit rate for comorbid HF. Although some HF events may have shifted from being coded as primary to comorbid diagnoses, the increase in comorbid HF ED visits occurred steadily throughout the observation period, so is unlikely to be driven by recent policy changes.
Despite reported population trends of better management and improved survival, we observed a stalled decline in the age-standardized HF-related mortality rate, with a significant decrease from 2006 to 2009, followed by no significant changes from 2010 to 2014. Given that reporting guidelines indicate HF should not be listed as the underlying cause of death if another plausible cause is identified, 35, 36 it is valuable to consider combined HF-related mortality, in which HF was listed as either an underlying or a contributing cause of death. Although not statistically significant, the observed recent increase in combined HF mortality after 2009 is consistent with other work. 37 This increase is also consistent with the broader context of cardiovascular disease in the United States, which reveals increases in mortality between 2010 and 2014 for numerous cardiovascular conditions 38, 39 and may reflect health effects of ongoing population trends, such as increasing physical inactivity, obesity, and diabetes mellitus. 1 The stalled decline in HF-related mortality, despite improvements in treatment and decreases in primary HF hospitalization, highlights the need for HF prevention, better treatment of risk factors, and improved surveillance. 26, 40 This study used nationally weighted, all-payer databases to estimate the event burden of HF among US adults. Although the data used were a key strength of the study, there were limitations. First, the Nationwide Emergency Department Sample and NIS are event-level databases, so patients could not be tracked over time, and patient-level information (such as prior events and diagnoses or annual per-patient cost) was not available. Second, this study did not examine burden of HF in outpatient clinical settings; HF may be present in 1.6% of all outpatient visits, increasing to 5.9% of outpatient visits among those aged ≥75 years. 41 The present study also did not capture burden of HF in nursing homes or long-term care facilities, and cost estimates did not include physician fees, which are not captured in HCUP. For these reasons, the true healthcare and cost burden of HF is likely to be considerably higher than estimated in this article. Third, criteria for identifying unique events excluded elective hospitalizations because management of these events (within acute care hospitals or outpatient surgical centers) may vary over time, and unique acute events were examined from 2006 to 2014. Fourth, analyses relied on accurate coding of HF and other conditions of interest, and biases may have resulted from underreporting or changes in diagnosis or coding patterns over time. 34, 42 Fifth, this study did not distinguish between stages or subcategories of HF. Sixth, this study did not examine hospital procedures during admissions, and because the data do not track patients over time, we were unable to examine longitudinal questions, such as whether certain procedures were associated with subsequent reductions in readmissions.
In addition to the impact of HF on human health, the economic burden that HF places on the healthcare system has been described as staggering 43 and is projected to rise as the population ages and survival of patients with HF improves. 3 In 2008 dollars, the total lifetime cost of HF was estimated at >$100 000 per person, with the majority of this cost because of hospitalizations. 43 Much of the financial burden falls to Medicare, as ≈three-quarters of ED visits and hospitalizations with primary or comorbid HF were among Medicare beneficiaries. Many hospitalizations for HF are regarded as preventable, 6 and efforts, such as the HRRP, have aimed to reduce burden and improve outcomes. However, further improvement is needed. Additional avenues are being explored, such as value-based models of care (including hospital value-based purchasing, bundled payments for care improvement, the merit-based incentive payment system, and accountable care organizations), 44 development and use of performance measures and performance improvement programs, and care coordination and transition programs, such as those that facilitate the hospital to home transition and provide in-home aftercare. 3 Improved treatment modalities may also improve outcomes, and more patients are using left ventricular assist devices as destination therapy rather than only as a bridge to transplant therapy. 45, 46 Another potential avenue for improvement of HF outcomes is use of cardiac rehabilitation. Cardiac rehabilitation has been found to reduce hospitalization, is recommended for stable outpatients with HF, and is covered as a Medicare fee for service benefit, yet only one-tenth of eligible patients with HF receive a referral. 47, 48 In addition, lack of medication adherence is one of the most common causes of cardiac decompensation and subsequent hospital admission, 6 while having a pharmacist or nurse responsible for medication reconciliation can reduce medication errors and reduce hospital-level HF readmissions. 49, 50 In conclusion, continued improvements in prevention, management, treatment, and surveillance of HF are important, given the considerable health impact of HF, the aging US population, and rising healthcare costs.
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